MangoGen Pharma, based in Montreal, Canada, is dedicated to addressing urgent unmet medical needs and developing the next generation of medical devices and products using its patented insect cell platform technology. Their clinical products include gene-delivering film dressings for diabetic foot ulcers, peripheral and coronary stents, and sutures. Additionally, they offer non-clinical over-the-counter skin care products such as luxury creams, gels, moisturizers, and face masks designed for skin rejuvenation and anti-wrinkle treatment.
MangoGen Pharma, based in Montreal, Canada, is dedicated to addressing urgent unmet medical needs and developing the next generation of medical devices and products using its patented insect cell platform technology.
International PCT/CA2014/050369. It covers all MangoGen products. Describes medical device such as a coronary stent that is coated with encapsulated with baculoviruses that deliver a gene to promotes and accelerates wound healing.
Baculoviruses are genetically modified to house a human gene or genes (e.g. VEGF, PDGFb)
Baculoviruses are protected by encapsulation in a biodegradable coating
Encapsulated baculoviruses are coated on to a medical device such as a film-dressing, suture, stent or in a gel
After deployment, the biodegradable coating dissolves – releasing the baculoviruses next to the target cells
Baculoviruses enter the local cells, transported to the nucleus where the human gene is transcribed.
Active growth factor is released
Film-Dressing
Locally released PDGFb promotes and accelerates wound healing. Gene expression is TRANSIENT. Baculoviral DNA is subsequently destroyed.
At Mangogen Pharma, we’re not just following the future; we’re creating it. Our pioneering biotech solutions are transforming patient care through innovative applications of our patented insect cell platform technology. Experience healthcare reimagined, where every advancement brings us closer to a world of enhanced healing and well-being.